RecruitingPhase 1Phase 2NCT04581512

Study to Evaluate the Safety and Tolerability of EP0042

A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies

Sponsor

Ellipses Pharma

Enrollment

70 participants

Start Date

Nov 2, 2020

Study Type

INTERVENTIONAL

Conditions

Acute Myeloid Leukemia Myelodysplastic Syndromes Chronic Myelomonocytic Leukemia

Summary

A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug, EP0042, in order to determine a dose, which is safe, well-tolerated and likely to be effective in treating AML (acute myeloid leukaemia).

Eligibility

Min Age: 18 Years

Inclusion Criteria13

General
Male or female patients aged ≥ 18 years of age, at the time of informed consent, with histological or cytological confirmation of AML
Ability to understand and provide written informed consent before any study-specific procedures, sampling, or analyses, including access to archival tumor tissue
Ability to swallow and retain oral medication
Sufficient life expectancy to allow the patient to complete at least 1 cycle (28 days) of the treatment period.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 at screening
In the opinion of the investigator, all other relevant medical conditions must be well-managed and stable for at least 28 days prior to first administration of study drug
Patients with pathologically confirmed/documented AML or MDS, as defined by the 2022 European LeukaemiaNet (ELN) recommendations, or CMML, as defined by World Health Organization (WHO) criteria, who have relapsed from or are refractory to previous therapy and have failed all (or are not eligible for/intolerant to) available approved therapies for their disease.
Patients with relapsed/refractory FLT3 WT AML.
Previous exposure to venetoclax, hypomethylating agent and/or FLT3 inhibitors (gilteritinib, midostorin, quizartinib, sorafenib) is allowed for relapsed/refractory AML patients.
Mutation status of patients must be known at trial entry.
Female patients should either be of non-child-bearing potential or must agree to use highly effective methods of contraception from Screening until 6 months following administration of the last dose of study drug
Male patients must use double barrier contraception from enrolment through treatment and for 6 months following administration of the last dose of study drug

Exclusion Criteria15

Patients with any of the following will not be included in the study:
Disease Under Study and Prior Anticancer Treatment
Suspected brain and/or leptomeningeal metastases that are symptomatic or untreated or that require current therapy
Acute promyelocytic leukemia (FAB:M3)
Systemic anti-cancer therapy for the disease under study within 2 weeks of the first dose of study treatment. If the previous anti-cancer therapy has a very long half-life and may interact with EP0042, e.g. a strong CYP3A4 inhibitor, the washout period may need to be increased for safety reasons but will be no longer than 3 weeks (Concomitant hydroxyurea is acceptable and will be permitted throughout the screening period and during first 6 cycles of study treatment)
Ongoing toxic manifestations of previous treatments that have not reduced to at least CTCAE Grade 1. Exceptions to this are alopecia or certain Grade 2 treatment related toxicities, which in the opinion of the Investigator should not exclude the patient.
Transplantation (allogeneic or autologous) within last 90 days, or on active immunosuppressive therapy for graft versus host disease in last 2 weeks
Laboratory Parameters
Patient with any out-of-range laboratory values defined as shown below.
• Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) \< 50 mL/ min
Inadequate liver function as demonstrated by
total serum bilirubin ≥ 1.5 times the upper limits of normal range (ULN) or
ALT ≥3 times the ULN or
AST ≥3 times the ULN or
AST or ALT ≥5 times the ULN in the presence of liver involvement by leukemia